Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View PlansCash Conversion
1.08x
SHILPAMED's operating cash flow exceeded net income in FY 2025, indicating earnings are backed by actual cash generation.
Free Cash Flow
₹-1.11B
SHILPAMED's free cash flow was negative at ₹-1.11B in FY 2025, down 132.7% from FY 2024. The company spent more on capital investments than it generated from operations.
CapEx Intensity
184.3%
Capital expenditure consumed 184.3% of operating cash flow in FY 2025 for SHILPAMED, typical of capital-intensive industries.
Hover the chart icon for YoY change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Net Income | 543.41M | 1.22B | |
| Cash flow Operating Activities | 1.37B | 1.32B | |
| Investments in PPE | -1.85B | -2.44B | |
| Cash flow Investing Activities | -1.67B | -1.99B | |
| Dividend Paid | 0 | 0 | |
| Cash flow Financing Activities | 467.75M | 626.54M | |
| Cash at beginning of period | 190.71M | 317.56M | |
| Cash at end of period | 317.56M | 285.24M | |
| Free Cash Flow | -478.92M | -1.11B |
Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025